-DOCSTART- -X- O
The -X- _ O
prevalence -X- _ O
of -X- _ O
preexisting -X- _ O
immunity -X- _ O
to -X- _ O
adenoviruses -X- _ O
in -X- _ O
the -X- _ O
majority -X- _ O
of -X- _ O
the -X- _ O
human -X- _ O
population -X- _ O
might -X- _ O
adversely -X- _ O
impact -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
adaptive -X- _ O
immune -X- _ O
responses -X- _ O
against -X- _ O
adenovirus -X- _ B-Intervention
vector-based -X- _ I-Intervention
vaccines. -X- _ I-Intervention
To -X- _ O
address -X- _ O
this -X- _ O
issue -X- _ O
, -X- _ O
we -X- _ O
primed -X- _ O
BALB -X- _ B-Patient
/ -X- _ I-Patient
c -X- _ I-Patient
mice -X- _ I-Patient
either -X- _ I-Patient
intranasally -X- _ I-Patient
( -X- _ I-Patient
i.n. -X- _ I-Patient
) -X- _ I-Patient
or -X- _ I-Patient
intramuscularly -X- _ I-Patient
( -X- _ I-Patient
i.m. -X- _ I-Patient
) -X- _ I-Patient
with -X- _ I-Patient
varying -X- _ I-Patient
doses -X- _ I-Patient
of -X- _ I-Patient
wild -X- _ I-Patient
type -X- _ I-Patient
( -X- _ I-Patient
WT -X- _ I-Patient
) -X- _ I-Patient
human -X- _ I-Patient
adenovirus -X- _ I-Patient
subtype -X- _ I-Patient
5 -X- _ I-Patient
( -X- _ I-Patient
HAd5 -X- _ I-Patient
) -X- _ I-Patient
. -X- _ I-Patient
Following -X- _ I-Patient
the -X- _ I-Patient
development -X- _ I-Patient
of -X- _ I-Patient
immunity -X- _ I-Patient
against -X- _ I-Patient
HAd5 -X- _ I-Patient
, -X- _ O
we -X- _ O
immunized -X- _ O
animals -X- _ O
via -X- _ O
the -X- _ O
i.n. -X- _ B-Intervention
or -X- _ I-Intervention
i.m. -X- _ I-Intervention
route -X- _ I-Intervention
of -X- _ I-Intervention
inoculation -X- _ I-Intervention
with -X- _ I-Intervention
a -X- _ I-Intervention
HAd -X- _ I-Intervention
vector -X- _ I-Intervention
( -X- _ I-Intervention
HAd-HA-NP -X- _ I-Intervention
) -X- _ I-Intervention
expressing -X- _ I-Intervention
the -X- _ I-Intervention
hemagglutinin -X- _ I-Intervention
( -X- _ I-Intervention
HA -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
nucleoprotein -X- _ I-Intervention
( -X- _ I-Intervention
NP -X- _ I-Intervention
) -X- _ I-Intervention
of -X- _ I-Intervention
A -X- _ I-Intervention
/ -X- _ I-Intervention
Vietnam -X- _ I-Intervention
/ -X- _ I-Intervention
1203 -X- _ I-Intervention
/ -X- _ I-Intervention
04 -X- _ I-Intervention
( -X- _ I-Intervention
H5N1 -X- _ I-Intervention
) -X- _ I-Intervention
influenza -X- _ I-Intervention
virus. -X- _ I-Intervention
The -X- _ O
immunogenicity -X- _ O
and -X- _ O
protection -X- _ O
results -X- _ O
suggest -X- _ O
that -X- _ O
low -X- _ B-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
vector -X- _ I-Outcome
immunity -X- _ I-Outcome
( -X- _ I-Outcome
< -X- _ I-Outcome
520 -X- _ I-Outcome
virus-neutralization -X- _ I-Outcome
titer -X- _ I-Outcome
) -X- _ I-Outcome
induced -X- _ I-Outcome
by -X- _ I-Outcome
priming -X- _ I-Outcome
mice -X- _ I-Outcome
with -X- _ I-Outcome
up -X- _ I-Outcome
to -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
7 -X- _ I-Outcome
) -X- _ I-Outcome
plaque -X- _ I-Outcome
forming -X- _ I-Outcome
units -X- _ I-Outcome
( -X- _ I-Outcome
p.f.u. -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ I-Outcome
HAd-WT -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
adversely -X- _ I-Outcome
impact -X- _ I-Outcome
the -X- _ I-Outcome
protective -X- _ I-Outcome
efficacy -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
vaccine. -X- _ I-Outcome
Furthermore -X- _ O
, -X- _ O
high -X- _ B-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
vector -X- _ I-Outcome
immunity -X- _ I-Outcome
( -X- _ I-Outcome
approximately -X- _ I-Outcome
1500 -X- _ I-Outcome
virus-neutralization -X- _ I-Outcome
titer -X- _ I-Outcome
) -X- _ I-Outcome
induced -X- _ I-Outcome
by -X- _ I-Outcome
priming -X- _ I-Outcome
mice -X- _ I-Outcome
with -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
8 -X- _ I-Outcome
) -X- _ I-Outcome
p.f.u. -X- _ I-Outcome
of -X- _ I-Outcome
HAd-WT -X- _ I-Outcome
were -X- _ I-Outcome
overcome -X- _ I-Outcome
by -X- _ I-Outcome
either -X- _ I-Outcome
increasing -X- _ I-Outcome
the -X- _ I-Outcome
vaccine -X- _ I-Outcome
dose -X- _ I-Outcome
or -X- _ I-Outcome
using -X- _ I-Outcome
alternate -X- _ I-Outcome
routes -X- _ I-Outcome
of -X- _ I-Outcome
vaccination. -X- _ I-Outcome
A -X- _ I-Outcome
further -X- _ I-Outcome
increase -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
priming -X- _ I-Outcome
dose -X- _ I-Outcome
to -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
9 -X- _ I-Outcome
) -X- _ I-Outcome
p.f.u. -X- _ I-Outcome
allowed -X- _ I-Outcome
only -X- _ I-Outcome
partial -X- _ I-Outcome
protection. -X- _ I-Outcome
These -X- _ O
results -X- _ O
suggest -X- _ O
possible -X- _ O
strategies -X- _ O
to -X- _ O
overcome -X- _ O
the -X- _ O
variable -X- _ O
levels -X- _ O
of -X- _ O
human -X- _ O
immunity -X- _ O
against -X- _ O
adenoviruses -X- _ O
, -X- _ O
leading -X- _ O
to -X- _ O
better -X- _ O
utilization -X- _ O
of -X- _ O
HAd -X- _ B-Intervention
vector-based -X- _ I-Intervention
vaccines -X- _ I-Intervention
. -X- _ O

